Pegylated interferon-alpha-2a for the treatment of ocular surface squamous neoplasia

Murtuza Nuruddin; Soma Rani Roy; Fahmida Hoque

doi:10.4103/ojo.ojo_146_21

Pegylated interferon-alpha-2a for the treatment of ocular surface squamous neoplasia

Oman J Ophthalmol. 2022 Mar 2;15(1):81-84. doi: 10.4103/ojo.ojo_146_21. eCollection 2022 Jan-Apr.

Authors

Murtuza Nuruddin¹, Soma Rani Roy², Fahmida Hoque²

Affiliations

¹ Chevron Eye Hospital and Research Centre, Chittagong, Bangladesh.
² Orbit, Oculoplasty and Oncology Clinic, Chittagong Eye Infirmary and Training Complex, Chittagong, Bangladesh.

Abstract

Ocular surface squamous neoplasia (OSSN) is the most common nonpigmented ocular surface neoplasm. Interferon-alpha (IFNα)-2b has been proved to be an effective immunotherapeutic agent to treat OSSN. We have used intralesional and topical (36 μg/ml) pegylated (peg) IFNα-2a to treat a recurrent surgically failed case of OSSN instead of IFNα-2b. In this case report, we have shared our initial experience with the novel use of peg-IFNα-2a to treat OSSN. According to our brief clinical experience, peg-IFNα-2a is nontoxic to ocular surface and has a promising role to treat OSSN.

Keywords: interferon-alpha-2a; interferon-alpha-2b; ocular surface neoplasm.

Publication types

Case Reports